Rose Ann Padua

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi request reprint PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia
    Rose Ann Padua
    LBCH INSERM E0 03, U462 and U396, Institut Universitaire d Hematologie, Hopital Saint Louis, AP HP 75010, Paris, France
    Nat Med 9:1413-7. 2003
  2. pmc BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
    Stephanie Beurlet
    Institut National de la Santé et de la Recherche Médicale U940, Paris, France
    Blood 122:2864-76. 2013
  3. doi request reprint DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model
    Kouichi Furugaki
    INSERM UMRS 940, Universite Paris 7, Paris, France
    Blood 115:653-6. 2010
  4. ncbi request reprint Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans
    Marie Robin
    LBCH INSERM U718, Hôpital Saint Louis APHP, Institut Universitaire d Hematologie, 1 avenue Claude Vellefaux, 75010, Paris, France
    Cancer Immunol Immunother 54:933-43. 2005
  5. doi request reprint Identification of JAK2 mutations in canine primary polycythemia
    Stephanie Beurlet
    Unité INSERM UMR S 940, Hopital Saint Louis, 1 avenue Claude Vellefaux, Paris, France
    Exp Hematol 39:542-5. 2011
  6. pmc Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?
    Stephanie Beurlet
    INSERM U940, Paris, France
    Haematologica 98:10-22. 2013
  7. ncbi request reprint Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells
    Jerome Larghero
    Service Clinique des Maladies du Sang, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Blood 105:3743-5. 2005
  8. ncbi request reprint BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia
    Nader Omidvar
    Institut National de la Sante et de la Recherche Medicale U718 and 728, Universite Paris 7 Denis Diderot, Faculte de Medicine, Institut Universitaire d Hématologie IFR105, Paris, France
    Cancer Res 67:11657-67. 2007
  9. ncbi request reprint Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?
    Terry J Gaymes
    Department of Haematological Medicine, Leukemia Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill Campus, London, United Kingdom
    Mol Cancer Res 4:563-73. 2006
  10. ncbi request reprint Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?
    Feyruz V Rassool
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201 1509, USA
    Cancer Res 67:8762-71. 2007

Collaborators

Detail Information

Publications10

  1. ncbi request reprint PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia
    Rose Ann Padua
    LBCH INSERM E0 03, U462 and U396, Institut Universitaire d Hematologie, Hopital Saint Louis, AP HP 75010, Paris, France
    Nat Med 9:1413-7. 2003
    ..When DNA vaccination and conventional ATRA therapy are combined, they induce protective immune responses against leukemia progression in mice and may provide a new approach to improve clinical outcome in human leukemia...
  2. pmc BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
    Stephanie Beurlet
    Institut National de la Santé et de la Recherche Médicale U940, Paris, France
    Blood 122:2864-76. 2013
    ..Myelodysplastic features persist underscoring targeting of BCL-2-mediated effects on MDS-AML transformation and survival of leukemic cells. ..
  3. doi request reprint DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model
    Kouichi Furugaki
    INSERM UMRS 940, Universite Paris 7, Paris, France
    Blood 115:653-6. 2010
    ..Our results demonstrate that DNA vaccination with ATRA confers the effective boosting of interferon-gamma-producing and cytotoxic T cells in the leukemic mice...
  4. ncbi request reprint Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans
    Marie Robin
    LBCH INSERM U718, Hôpital Saint Louis APHP, Institut Universitaire d Hematologie, 1 avenue Claude Vellefaux, 75010, Paris, France
    Cancer Immunol Immunother 54:933-43. 2005
    ..We review different immunotherapy strategies tested in preclinical animal models of AML and the human trials that spurred from encouraging results obtained in animal models, demonstrate the feasibility of immunotherapy in AML patients...
  5. doi request reprint Identification of JAK2 mutations in canine primary polycythemia
    Stephanie Beurlet
    Unité INSERM UMR S 940, Hopital Saint Louis, 1 avenue Claude Vellefaux, Paris, France
    Exp Hematol 39:542-5. 2011
    ..As the canine JAK2 gene shares strong homology with its human counterpart, we looked for the presence of JAK2 mutations in dogs with an elevated hematocrit...
  6. pmc Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?
    Stephanie Beurlet
    INSERM U940, Paris, France
    Haematologica 98:10-22. 2013
    ....
  7. ncbi request reprint Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells
    Jerome Larghero
    Service Clinique des Maladies du Sang, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Blood 105:3743-5. 2005
    ..Thus tipifarnib may specifically target PV stem cells and may be of clinical interest in the treatment of patients with PV...
  8. ncbi request reprint BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia
    Nader Omidvar
    Institut National de la Sante et de la Recherche Medicale U718 and 728, Universite Paris 7 Denis Diderot, Faculte de Medicine, Institut Universitaire d Hématologie IFR105, Paris, France
    Cancer Res 67:11657-67. 2007
    ..The colocalization of BCL-2 and RAS in the bone marrow of MDS/AML patients offers targeting either oncogene as a therapeutic strategy...
  9. ncbi request reprint Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?
    Terry J Gaymes
    Department of Haematological Medicine, Leukemia Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill Campus, London, United Kingdom
    Mol Cancer Res 4:563-73. 2006
    ..Our data indicate that induction of apoptosis by HDI may result predominantly through accumulation of excessive DNA damage in leukemia cells, leading to activation of apoptosis...
  10. ncbi request reprint Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?
    Feyruz V Rassool
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201 1509, USA
    Cancer Res 67:8762-71. 2007
    ..These data suggest treatment strategies that target RAS/RAC pathways and ROS production in human MDS/AML...